Immunotherapy for Liver Cancer

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, characterized by a poor prognosis and rising incidence. While HCC arises from diverse etiologies and employs multiple mechanisms to evade immune surveillance, recent advances in immunotherapy have revolutionized treatment approaches. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have emerged as pivotal therapies for advanced HCC, alongside promising strategies such as therapeutic cancer vaccines, engineered cytokines, and adoptive cell therapies, driven by rapid progress in synthetic biology and genetic engineering.

References:

[1]. Takuji Okusaka, et al. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. Review ESMO Open. 2018 Dec 10;3(Suppl 1):e000455.

Immunotherapy for Liver Cancer (1):

Targets:	Bacterial (1) Biochemical Assay Reagents (1)

Cat. No.	Product Name	CAS No.	Purity	Chemical Structure

HY-W010989

Gly-His-Lys acetate	72957-37-0	99.68%
Gly-His-Lys acetate is a natural, circulating regulatory and antimicrobial tripeptide derived from extracellular matrix proteins. Gly-His-Lys acetate binds Cu²⁺ to support copper enzyme activation, antioxidant processes, cellular bioenergetics, and the synthesis of elastin, collagen and catecholamines. Gly-His-Lys acetate regulates cell growth, differentiation and tissue repair, and exerts regenerative, anxiolytic, anti-inflammatory, analgesic and immunosuppressive activities. Gly-His-Lys acetate induces liver degenerative changes. Gly-His-Lys acetate can be used for the research of infections, anxiety, pain-related behaviors and immune-associated liver diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.